Venetoclax/Venetoclax Dosing Guide: How to Take for Best Effects

Venetoclax is an oral, highly selective BCL-2 inhibitor widely used to treat patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and acute myeloid leukemia (AML) under certain conditions. In order to maximize the therapeutic effect of venetoclax while reducing potential side effects, especially the risk of tumor lysis syndrome (TLS), its dosage regimen needs to strictly follow the principle of gradual increase and be individually adjusted according to specific indications.

In the treatment of CLL or SLL, the initial period of taking venetoclax is usually a 5-week "dose escalation period", starting with 20 mg daily, and gradually increasing the dose every week: 50 mg in the 2nd week, 100 mg in the 3rd week, 200 mg in the 4th week, and reaching the target maintenance dose of 400 mg/day in the 5th week. This approach can significantly reduce the risk of TLS caused by rapid tumor cell rupture. During this period, doctors will decide whether hospitalization or additional pretreatment measures are needed based on the patient's white blood cell load, tumor size, and renal function, such as hydration and the use of drugs such as allopurinol or raloxifene to prevent hyperuricemia.

After entering the maintenance phase, venetoclax needs to be taken orally daily400 mg and used in combination with other drugs (such as obinutuzumab). Treatment usually lasts 12 to 24 months, depending on the patient's response to treatment and tolerance of adverse effects. The medicine should be taken with food to enhance drug absorption. At the same time, the tablet should be swallowed whole each time and avoid chewing, crushing or breaking. If gastrointestinal reactions, leukopenia, or other toxic reactions occur, doctors may adjust the dose or temporarily interrupt treatment based on the severity of the adverse reactions.

In patients with acute myeloid leukemia (AML), venetoclax is often given in combination with azacitidine, decitabine, or low-dose cytarabine. In this type of combination, venetoclax does not require a 5-week escalation period, but a medication period of 7 to 28 days is usually carried out from the first cycle (depending on the specific combination drug), and the dose or cycle is adjusted based on the patient's bone marrow suppression degree.

Reference materials:https://www.venclexta.com/